JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients

• DOI: 10.1016/j.jdcr.2023.01.020
• Publication Date: 2023-02-04T16:53:38Z
• Authors: Neda Shahriari; Bruce Strober; Mona Shahriari
• Keywords: Dupilumab; Refractory (planetary science); Pathogenesis; Interleukin 13; Rescue therapy

Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disorder with heterogeneous clinical presentation and the cardinal symptom of itch, that results in significant patient burden decrease patient's quality life.1 The pathogenesis AD multifactorial from an immune response skewed toward Th2 axis, displaying upregulation key cytokines, including interleukin 4 (IL-4), IL-5, IL-13, IL-31.2,3 Dupilumab, biologic, which inhibits IL-4 IL-13 signaling via inhibition receptor alpha subunit, was first targeted treatment approved for AD.